Copperleaf Capital LLC Has $1.26 Million Holdings in Cencora, Inc. $COR

Copperleaf Capital LLC cut its stake in Cencora, Inc. (NYSE:COR) by 4.4% in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 4,193 shares of the company’s stock after selling 192 shares during the period. Copperleaf Capital LLC’s holdings in Cencora were worth $1,257,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently made changes to their positions in the stock. Atlantic Edge Private Wealth Management LLC lifted its stake in shares of Cencora by 70.0% in the second quarter. Atlantic Edge Private Wealth Management LLC now owns 85 shares of the company’s stock valued at $25,000 after buying an additional 35 shares during the period. Costello Asset Management INC acquired a new position in Cencora in the 1st quarter valued at approximately $28,000. University of Texas Texas AM Investment Management Co. bought a new stake in shares of Cencora in the 1st quarter worth approximately $39,000. Caitong International Asset Management Co. Ltd bought a new stake in shares of Cencora in the 2nd quarter worth approximately $61,000. Finally, ANTIPODES PARTNERS Ltd acquired a new stake in shares of Cencora during the 2nd quarter worth approximately $61,000. Institutional investors own 97.52% of the company’s stock.

Cencora Price Performance

Shares of COR stock opened at $361.80 on Wednesday. Cencora, Inc. has a 52 week low of $223.92 and a 52 week high of $369.00. The stock has a market capitalization of $70.14 billion, a PE ratio of 37.22, a PEG ratio of 1.56 and a beta of 0.63. The company has a debt-to-equity ratio of 3.64, a quick ratio of 0.53 and a current ratio of 0.90. The stock’s fifty day moving average is $323.97 and its 200-day moving average is $303.25.

Cencora (NYSE:COR) last posted its quarterly earnings data on Wednesday, November 5th. The company reported $3.84 earnings per share for the quarter, beating the consensus estimate of $3.79 by $0.05. Cencora had a net margin of 0.60% and a return on equity of 267.36%. The firm had revenue of $83.73 billion during the quarter, compared to analysts’ expectations of $83.36 billion. During the same quarter last year, the company posted $3.34 EPS. The company’s quarterly revenue was up 5.9% compared to the same quarter last year. Cencora has set its FY 2026 guidance at 17.450-17.75 EPS. Equities research analysts expect that Cencora, Inc. will post 15.37 EPS for the current fiscal year.

Cencora Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Monday, December 1st. Stockholders of record on Friday, November 14th will be paid a dividend of $0.60 per share. This represents a $2.40 annualized dividend and a dividend yield of 0.7%. This is a boost from Cencora’s previous quarterly dividend of $0.55. The ex-dividend date of this dividend is Friday, November 14th. Cencora’s payout ratio is currently 30.19%.

Analyst Ratings Changes

A number of equities research analysts have weighed in on the stock. Robert W. Baird lifted their price target on shares of Cencora from $355.00 to $395.00 and gave the stock an “outperform” rating in a research note on Thursday, November 6th. JPMorgan Chase & Co. lifted their target price on shares of Cencora from $344.00 to $417.00 and gave the company an “overweight” rating in a research report on Tuesday, November 11th. TD Cowen upped their target price on shares of Cencora from $350.00 to $400.00 and gave the company a “buy” rating in a research note on Monday, November 10th. Weiss Ratings restated a “buy (b-)” rating on shares of Cencora in a research note on Thursday, October 30th. Finally, Evercore ISI set a $400.00 price objective on Cencora and gave the company an “outperform” rating in a report on Thursday, November 6th. Nine equities research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $371.09.

Insider Activity

In other Cencora news, Chairman Steven H. Collis sold 31,350 shares of the business’s stock in a transaction dated Tuesday, September 16th. The stock was sold at an average price of $289.86, for a total transaction of $9,087,111.00. Following the completion of the sale, the chairman directly owned 305,913 shares of the company’s stock, valued at approximately $88,671,942.18. The trade was a 9.30% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, CEO Robert P. Mauch sold 5,097 shares of the firm’s stock in a transaction dated Monday, October 20th. The shares were sold at an average price of $326.80, for a total transaction of $1,665,699.60. Following the completion of the transaction, the chief executive officer directly owned 37,940 shares in the company, valued at $12,398,792. This trade represents a 11.84% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last quarter, insiders sold 41,544 shares of company stock worth $12,230,941. 10.80% of the stock is owned by company insiders.

Cencora Company Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.